

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 MARCH 2015

ERRATA

(1) This Erratum corrects the entry for **Olanzapine** in the 1 March 2015 Schedule.

The following Note should appear in the Schedule entry for all Olanzapine items. The Note was omitted for items 1024X, 1037N, 1041T, 1042W, 3381Y, 3382B, 3384D, and 3385E.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

(2) This Erratum corrects the entry for **Tocilizumab** in the 1 March 2015 Schedule.

The Notes with the heading “TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS” and with the subheadings:

- (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.
- (2) Swapping therapy.
- (3) Baseline measurements to determine response.

are not relevant to the section 100 Highly Specialised Drugs listing of Tocilizumab for systemic juvenile idiopathic arthritis. These Notes do not apply to the PBS availability of items 1423X, 1464C, 1419Q, 1481Y, 1482B and 1476Q.

(3) The listing for testosterone in the 1 March 2015 Schedule is incorrect and should appear as follows:

Code	Name, Restriction, Manner of Administration and Form	Max Qty (Packs)	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
	TESTOSTERONE <u>Authority required</u> Androgen deficiency Clinical criteria: Patient must have an established pituitary or testicular disorder. Population criteria: Patient must be male. <u>Authority required</u> Androgen deficiency						

Clinical criteria:

Patient must have an established pituitary or testicular disorder other than ageing.

Population criteria:

Patient must be male.

AND

Patient must be aged 40 years or older.

Androgen deficiency is defined as:

- (i) testosterone level of less than 8 nmol per litre; OR
- (ii) testosterone level between 8 and 15 nmol per litre with high luteinising hormone (LH) (greater than 1.5 times the upper limit of the eugonadal reference range for young men).

Androgen deficiency must be confirmed by at least two morning blood samples taken on different mornings.

Authority required

Micropenis

Population criteria:

Patient must be male.

AND

Patient must be under 18 years of age.

Authority required

Pubertal induction

Population criteria:

Patient must be male.

AND

Patient must be under 18 years of age.

Authority required

Constitutional delay of growth or puberty.

Population criteria:

Patient must be male.

AND

Patient must be under 18 years of age.

8830R	Testosterone 1% (50 mg/5 g) gel, 30 x 5 g sachets	£1	5	..	95.46	37.70	Testogel	HB
2341F	testosterone 2% (30 mg/1.5 mL actuation) transdermal solution, 60 actuations	£1	5	..	82.79	37.70	Axiron	LY
8460G	testosterone 2.5 mg/24 hours patch, 60	£1	5	..	96.18	37.70	Androderm	GN
8619P	testosterone 5 mg/24 hours patch, 30	£1	5	..	96.18	37.70	Androderm	GN

TESTOSTERONE ENANTHATE**Authority required**

Androgen deficiency

Clinical criteria:

Patient must have an established pituitary or testicular disorder.

Population criteria:

Patient must be male.

Authority required

Androgen deficiency

Clinical criteria:

Patient must have an established pituitary or testicular disorder other than ageing.

Population criteria:

Patient must be male.

AND

Patient must be aged 40 years or older.

Androgen deficiency is defined as:

(iii) testosterone level of less than 8 nmol per litre; OR

(iv) testosterone level between 8 and 15 nmol per litre with high luteinising hormone (LH) (greater than 1.5 times the upper limit of the eugonadal reference range for young men).

Androgen deficiency must be confirmed by at least two morning blood samples taken on different mornings.

Authority required

Micropenis

Population criteria:

Patient must be male.

AND

Patient must be under 18 years of age.

Authority required

Pubertal induction

Population criteria:

Patient must be male.

AND

Patient must be under 18 years of age.

Authority required

Constitutional delay of growth or puberty.

Population criteria:

Patient must be male.

AND

Patient must be under 18 years of age.

2114G	testosterone enanthate 250 mg/mL injection, 3 x 1 mL syringes	1	3	..	33.82	34.97	Primoteston Depot	BN
-------	---	---	---	----	-------	-------	-------------------	----

TESTOSTERONE UNDECANOATE

Authority required

Androgen deficiency

Clinical criteria:

Patient must have an established pituitary or testicular disorder.

Population criteria:

Patient must be male.

Authority required

Androgen deficiency

Clinical criteria:

Patient must have an established pituitary or testicular disorder other than ageing.

Population criteria:

Patient must be male.

AND

Patient must be aged 40 years or older.

Androgen deficiency is defined as:

(v) testosterone level of less than 8 nmol per litre; OR

(vi) testosterone level between 8 and 15 nmol per litre with high luteinising hormone (LH) (greater than 1.5 times the upper limit of the eugonadal reference range for young men).

Androgen deficiency must be confirmed by at least two morning blood samples taken on different mornings.

Authority required

Micropenis

Population criteria:

Patient must be male.

AND

Patient must be under 18 years of age.

Authority required

Pubertal induction

Population criteria:

Patient must be male.

AND

Patient must be under 18 years of age.

Authority required

Constitutional delay of growth or puberty.

Population criteria:

Patient must be male.

AND

Patient must be under 18 years of age.

9004X	testosterone undecanoate 1 g/4 mL injection, 1 x 4 mL ampoule	1	1	..	147.75	37.70	Reandron 1000	BN
10205D	testosterone undecanoate 1 g/4 mL injection, 1 x 4 mL vial	1	1	..	147.75	37.70	Reandron 1000	BN
2115H	testosterone undecanoate 40 mg capsule, 60	1	5	..	37.87	37.70	Andriol Testocaps	MK